Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PH-797804 material sparing · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | - |
| Sequence 2 | EXPERIMENTAL | - |
| Sequence 3 | EXPERIMENTAL | - |
| Sequence 4 | EXPERIMENTAL | - |
| Sequence 5 | EXPERIMENTAL | oral, 6mg, single dose |
| Sequence 6 | EXPERIMENTAL | oral, 6mg, single dose |
| Name | Type | Description |
|---|---|---|
| PH-797804 material sparing tablet | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 with sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 without sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
Inclusion Criteria: * Healthy male and female subjects of non-childbearing potential between the ages of 21 and 55. * No evidence of active or latent TB. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence, including abnormal clinical laboratory paramete...
PH-797804 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in clinical development to assess its safety, tolerability, and relative oral bioavailability. The drug is being developed by Pfizer, Inc. (PFE).
PH-797804 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is an investigational small molecule currently in Phase 1 clinical development.
PH-797804 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 study in healthy volunteers has been completed to evaluate its safety, tolerability, and relative oral bioavailability of three formulations.
PH-797804 has one completed clinical trial, NCT01226693, titled 'A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804'. This Phase 1 study enrolled 18 healthy volunteers in Singapore and was completed.
Yes, PH-797804 material sparing refers to the same drug, PH-797804. The term 'material sparing' likely describes a formulation or manufacturing approach used in the clinical trial to reduce the amount of drug substance needed, but the active pharmaceutical ingredient is identical.